4. Bibliografía

Bibliografía

-Contrò G, Tallerico R, Dattilo V, Fabiani F, Enzo MV, Hladnik U, Dastoli S, Nisticò SP, Colao E, Perrotti N, Iuliano R. A novel ABCC6 variant causative of pseudoxanthoma elasticum. Hum Genome Var. 2019; 20;6:30.

–Kim D, Seo EJ, Song YS, Suh CH, Kim JW, Kim DJ, Suh DC. Current Status of Clinical Diagnosis and Genetic Analysis of Hereditary Hemorrhagic Telangiectasia in South Korea: Multicenter Case Series and a Systematic Review. Neurointervention. 2019; 14:91-98.

-Orizaga-Y-Quiroga TL, Villarreal-Martínez A, Jaramillo-Moreno G, Ocampo-Candiani J. Osler-Weber-Rendu Syndrome in Relation to Dermatology. Actas Dermosifiliogr. 2019; 110:526-532.

-Wada S, Miyake M, Kido A, Kamei T, Hiragi S, Ikeda HO, Hata M, Ueshima H, Tsujikawa A, Tamura H. Epidemiology of Angioid Streaks and Pseudoxanthoma Elasticum (2011-2020): A Nationwide Population-based Cohort Study. Ophthalmol Sci. 2023; 4(2):100370.

-Loewinger AS, Pfau M, Herrmann P, Holz FG, Pfau K. Choriocapillaris Flow Signal Impairment in Patients With Pseudoxanthoma Elasticum. Invest Ophthalmol Vis Sci. 2023; 64(2):21.

-Martin, 2026.

-Weigelt MA, Franklin MJ, Mathur D, Billings SD, Ronen S. Pseudoxanthoma-elasticum-like changes on the soft palate. J Cutan Pathol. 2023; 50(8):730-733.

-Beaussier T, Rouffet A, Dejean M, Deranque C, Martin L, Rousseau P. Treatment of skin lesions related to pseudoxanthoma elasticum in plastic surgery. Ann Chir Plast Esthet. 2025; 70(2):104-111.

-Brokamp G, Mori M, Faith EF. Pseudoxanthoma Elasticum. JAMA Dermatol. 2022; 158(1):100.

-Tortora A, Riccioni ME, Gaetani E, Ojetti V, Holleran G, Gasbarrini A. Rendu-Osler-Weber disease: a gastroenterologist’s perspective. Orphanet J Rare Dis. 2019; 14:130.

-Dupuis-Girod S, Cottin V, Shovlin CL. The Lung in Hereditary Hemorrhagic Telangiectasia. Respiration. 2017; 94:315-330.

-Robard L, Michel J, Prulière Escabasse V, Bequignon E, Vérillaud B, Malard O, Crampette L; SFORL Work-Group. Guidelines of the French Society of Otorhinolaryngology (SFORL) (short version). Specific treatment of epistaxis in Rendu-Osler-Weber disease. Eur Ann Otorhinolaryngol Head Neck Dis. 2017; 134:37-41.

-Contegiacomo A, Del Ciello A, Rella R, Attempati N, Coppolino D, Larici AR, Di Stasi C, Marano G, Manfredi R. Pulmonary arteriovenous malformations: what the interventional radiologist needs to know. Radiol Med. 2019. doi: 10.1007/s11547-019-01051-7.

-Macri A, Wilson AM, Shafaat O, Sharma S. Osler-Weber-Rendu Disease. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.

-Pujol RM, Casanova JM, Egido R, Pujol J, de Moragas JM. Multiple familial pilomatricomas: a cutaneous marker for Gardner syndrome? Pediatr Dermatol. 1995; 12:331-5.

-Seehra J, Patel S, Bryant C. Gardner’s Syndrome revisited: a clinical case and overview of the literature. J Orthod. 2016; 43:59-64.

-Juhn E, Khachemoune A. Gardner syndrome: skin manifestations, differential diagnosis and management. Am J Clin Dermatol. 2010; 11:117-22.

-Khanna K, Khanna V, Bhatnagar V. Peutz-Jeghers syndrome: need for early screening. BMJ Case Rep. 2018; 11. pii: e225076

-Wu M, Krishnamurthy K. Peutz-Jeghers Syndrome. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018-2019.

-Horikawa H, Hirai I, Umegaki-Arao N, Amagai M, Saito M. Alopecia in Cronkhite-Canada syndrome: Is it truly telogen effluvium? Australas J Dermatol. 2019; doi: 10.1111/ajd.13073.

-Li Y, Luo HQ, Wu D, Xue XW, Luo YF, Xiao YM, Chen J, Zhou WX. Clinicopathologic features of Cronkhite-Canada syndrome and the significance of IgG4-positive plasma cells infiltration. Zhonghua Bing Li Xue Za Zhi. 2018; 47:753-757.

-Song Y, Cao J, Wang J. Cronkhite-Canada syndrome. Dig Liver Dis. 2026; 58(2):273-274.

-Wu S, Wu J, Wang Y. Cronkhite-Canada syndrome presenting with chronic diarrhea: A case report. Medicine (Baltimore). 2025; 104(44):e45458.

-Wang N, Xiang Y, Tao L, Ming W, Ren L, Huang T, Yang G, Gao J, Ren Q, Zhu P, Huang M. Cronkhite-Canada syndrome: A case report and literature review. Medicine (Baltimore). 2024; 103(43):e40242.

–Richter L, Rappersberger K. Hauterscheinungen bei chronisch entzündlichen Darmerkrankungen: Morbus Crohn und Colitis ulcerosa. Hautarzt. 2016; 67:940-947.

–Cui RZ, Bruce AJ, Rogers RS 3rd. Recurrent aphthous stomatitis. Clin Dermatol. 2016; 34:475-81.

–Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, Aractingi S, Khosrotehrani K. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008; 87:281-93.

-Malik TF, Aurelio DM. Extraintestinal Manifestations of Inflammatory Bowel Disease. 2023 Mar 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.

-Weber V, Weimann K, Kolm I, Meier-Schiesser B. Erythema nodosum. Dermatologie (Heidelb). 2025; 76(1):40-48.

-Filosa A, Filosa G. Neutrophilic dermatoses: a broad spectrum of disease. G Ital Dermatol Venereol. 2018; 153:265-272.

–Kridin K, Cohen AD, Amber KT. Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis. Am J Clin Dermatol. 2018; 19:479-487.

–Plumptre I, Knabel D, Tomecki K. Pyoderma Gangrenosum: A Review for the Gastroenterologist. Inflamm Bowel Dis. 2018; 24:2510-2517.

–Maverakis E, Ma C, Shinkai K, Fiorentino D, Callen JP, Wollina U, Marzano AV, Wallach D, Kim K, Schadt C, Ormerod A, Fung MA, Steel A, Patel F, Qin R, Craig F, Williams HC, Powell F, Merleev A, Cheng MY. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018; 154:461-466.

–Toh JWT, Young CJ, Rickard MJFX, Keshava A, Stewart P, Whiteley I. Peristomal pyoderma gangrenosum: 12-year experience in a single tertiary referral centre. ANZ J Surg. 2018; 88:E693-E697.

–Partridge ACR, Bai JW, Rosen CF, Walsh SR, Gulliver WP, Fleming P. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials. Br J Dermatol. 2018; 179:290-295.

-Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzano AV. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. Am J Clin Dermatol. 2022; 23(5):615-634.

-Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG. Pyoderma Gangrenosum: Treatment Options. Drugs. 2023; 83(14):1255-1267.

–Cohen PR. Sweet’s síndrome -a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007; 2:34.

–Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A. Sweet Syndrome: A Review and Update. Actas Dermosifiliogr. 2016; 107:369-78.

–Nelson CA, Noe MH, McMahon CM, Gowda A, Wu B, Ashchyan HJ, Perl AE, James WD, Micheletti RG, Rosenbach M. Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018; 78:303-309.

–Nofal A, Abdelmaksoud A, Amer H, Nofal E, Yosef A, Gharib K, Albalat W, Eldesouky F, Ebrahim HM, Abdelshafy AS, Fayed H. Sweet’s syndrome: diagnostic criteria revisited. J Dtsch Dermatol Ges. 2017; 15:1081-1088.

–Cohen PR. Sweet’s síndrome -a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007; 2:34.

–Raza S, Kirkland RS, Patel AA, Shortridge JR, Freter C. Insight into Sweet’s syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013; 42:1516-22.

–Rochet NM, Chavan RN, Cappel MA, Wada DA, Gibson LE. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013; 69:557-64.

-Yadav A, Gaurav V, Yadav D, Garg S. Bleomycin-induced Sweet’s syndrome. Indian J Pharmacol. 2025; 57(5):356-358.

–Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol. 2018; 79:987-1006.

–Raza S, Kirkland RS, Patel AA, Shortridge JR, Freter C. Insight into Sweet’s syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013; 42:1516-22.

-Nikolaishvili M, Di Lernia V. Bowel-Associated Dermatosis-Arthritis Syndrome (BADAS). Dermatol Pract Concept. 2026; 16(1):6104.

-Aromolo IF, Simeoli D, Maronese CA, Altomare A, Noviello D, Caprioli F, Marzano AV. The Bowel-Associated Arthritis-Dermatosis Syndrome (BADAS): A Systematic Review. Metabolites. 2023; 13(7):790.

-Martínez Jiménez S. Cutaneous Manifestations of Liver Disease: A Narrative Review. Cureus. 2024; 16(9):e70357.

-Nelson M, Mulani SR, Saguil A. Evaluation of Jaundice in Adults. Am Fam Physician. 2025; 111(1):25-30.

-Sack JS, Liu AF, Gray M, Roat J, Zucker SD. Association of Terry Nails With Liver Cirrhosis. Am J Gastroenterol. 2021; 116(12):2455-2458.

-Azimi SZ, Lerner EA. Chronic kidney disease and itch. Itch (Phila). 2024; 9(3):e0076.

-Uppal NN, Corona A, Fishbane S. Pruritus in chronic kidney disease. Curr Opin Nephrol Hypertens. 2022 Sep 1;31(5):435-441.

-Szepietowska M, Lisicki B, Jaworek AK, Krajewska M, Szepietowski JC. Half-and-Half Nails and Terry’s Nails: Distinct Nail Manifestations of the Same Underlying Chronic Kidney Disease. Balkan Med J. 2026; 43(6):343-344.

-Singal A, Liu J, Cowper SE, Ko CJ, Kroshinsky D, Lipner HI, Robinson-Bostom L, Yosipovitch G, Lipner SR. Part I. Dermatologic Manifestations in Patients with Kidney Disease. J Am Acad Dermatol. 2025:S0190-9622(25)02360-6.

–Junghetu MA, Tutunaru CV, Ianoși SL, Georgescu CV, Orzan OA. Acquired Reactive Perforating Collagenosis-A Rare Entity Occurring Within Common Disorders: A Systematic Review and Our Personal Experience. J Clin Med. 2026; 15(1):391.

-Mullins TB, Sickinger M, Zito PM. Reactive Perforating Collagenosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.

-Alenzi F. Reactive perforating collagenosis and systemic lupus erythematosus: A rare case report. Medicine (Baltimore). 2022; 101(48):e32138.

-Davies OMT, Anakwenze L, DeSimone MS, Nambudiri VE. Reactive Perforating Collagenosis: Answer. Am J Dermatopathol. 2024; 46(10):714.

-Papadopoulou MM, Karampinis E, Sgouros D, Sakellaropoulou S, Lazaridou E, Lallas A, et al. Dermoscopy of Acquired Perforating Dermatoses: A Case Series and Review of the Literature. Life. 2025; 15:1786.

-Mullins TB, 2025; Su Y, Cui W. A case report on acquired reactive perforating collagenosis. Medicine (Baltimore). 2024; 103(29):e39071.

-Glennon CM, Nigwekar SU, Kroshinsky D, Tucker JK. Skin Disorders in Kidney Disease: Core Curriculum 2026. Am J Kidney Dis. 2026; 87(1):102-114.

-Mullins TB, Zito PM. Reactive Perforating Collagenosis. StatPearls. Treasure Island (FL): StatPearls Publishing; 2019 Jan-2019 Aug 3.

–Marano AL, Selim MA, Cardones AR, Burton CS. Nodular amyloidosis in a patient with systemic scleroderma. Dermatol Online J. 2018; 24(9). pii: 13030/qt85b030dk.

-Yang M, Li LF, Chang JM. Histopathological findings of primary cutaneous lichenoid and macular amyloidosis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009; 31:31-3.

–D’Aguanno V, Ralli M, Artico M, Russo FY, Scarpa A, Fiore M, Tirassa P, Severini C, de Vincentiis M, Greco A. Systemic Amyloidosis: a Contemporary Overview. Clin Rev Allergy Immunol. 2019. doi: 10.1007/s12016-019-08759-4.

-Hazenberg BP. Amyloidosis: a clinical overview. Rheum Dis Clin North Am. 2013; 39:323-45.

-Vyas K, Morgaonkar M, Gupta S, Jain SK. Primary Systemic Amyloidosis with Unusual Dermatological Manifestations: A Rare Case Report. Indian J Dermatol. 2016; 61:216-8.

-Kumar S, Sengupta RS, Kakkar N, Sharma A, Singh S, Varma S. Skin involvement in primary systemic amyloidosis. Mediterr J Hematol Infect Dis. 2013; 5:e2013005.

-Flores-Bozo LR, Echevarría-Keel J, Domínguez-Cherit J, Esquivel-Pedraza L, Méndez-Flores S. Mucocutaneous manifestations in systemic amyloidosis A retrospective analytical study in a tertiary care center. Int J Dermatol. 2019; 58:1062-1068.

-Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016; 387(10038):2641-2654.

–Weidner T, Illing T, Elsner P. Primary Localized Cutaneous Amyloidosis: A Systematic Treatment Review. Am J Clin Dermatol. 2017; 18:629-642.

-Choi JY, Sippe J, Lee S. Acitretin for lichen amyloidosus. Australas J Dermatol. 2008; 49:109-13.

-Grimmer J, Weiss T, Weber L, Meixner D, Scharffetter-Kochanek K. Successful treatment of lichen amyloidosis with combined bath PUVA photochemotherapy and oral acitretin. Clin Exp Dermatol. 2007; 32:39-42.

-Hegenbart U, Farid KMN, Schönland S. Amyloidosen. Dtsch Med Wochenschr. 2024; 149(21):1270-1275.

-Spanggaard MB, Hansen CT, Maiborg M, Rojek AM, Vestergaard S, Beck HC, Møller HE, Abildgaard N. Amyloidosis is a disease with many faces. Ugeskr Laeger. 2023; 185(1):V08220479.

-Janodia R, Schwartz RA. Cutaneous Amyloidosis: An Updated Approach Focusing on Macular Amyloidosis. Dermatology. 2026;242(3):329-333.

-Llamas-Molina JM, Velasco-Amador JP, De la Torre-Gomar FJ, Carrero-Castaño A, Ruiz-Villaverde R. Localized Cutaneous Nodular Amyloidosis: A Specific Cutaneous Manifestation of Sjögren’s Syndrome. Int J Mol Sci. 2023; 24(8):7378.

-Wang QX, Ye Q, Zhou KY, Luo SY, Fang S. Systematic review and meta-analysis of treatments and outcomes in primary localized cutaneous amyloidosis. Clin Exp Dermatol. 2025; 50(7):1343-1354.

-Alvarez-Ruiz SB, García-Río I, Daudén E. Amiloidosis sistémicas. Actas Dermosifiliogr. 2005; 96(2):69-82.

-Ma C, Hong F, Yang S. Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules. 2022; 27(4):1210.

–García-Lozano JA, Ocampo-Candiani J, Martínez-Cabriales SA, Garza-Rodríguez V. An Update on Calciphylaxis. Am J Clin Dermatol. 2018; 19:599-608.

-Jiménez-Gallo D, Ossorio-García L, Linares-Barrios M. Calcinosis Cutis and Calciphylaxis. Actas Dermosifiliogr. 2015; 106:785-94; Cucchiari D, 2018.

–Cucchiari D, Torregrosa JV. Calciphylaxis in patients with chronic kidney disease: A disease which is still bewildering and potentially fatal. Nefrología. 2018; 38:579-586.

-Nigwekar SU. Calciphylaxis. Curr Opin Nephrol Hypertens. 2017; 26:276-281.

-Dutta P, Chaudet KM, Nazarian RM, Kroshinsky D, Nigwekar SU. Correlation between clinical and pathological features of cutaneous calciphylaxis. PLoS One. 2019; 14:e0218155.

-Yu WY, Bhutani T, Kornik R, Pincus LB, Mauro T, Rosenblum MD, Fox LP. Warfarin-Associated Nonuremic Calciphylaxis. JAMA Dermatol. 2017; 153:309-314.

–Galassi A, Perna F, De Nicola E, Moneghini L, Sganzaroli AB, Cozzolino M. Calciphylaxis in a dialysis patient treated by intralesional and systemic sodium thiosulphate on top of multifactorial intervention. Clin Kidney J. 2018; 12:546-549.

-Zuhaili B, Al-Talib K. Successful Treatment of Single Infected Calciphylaxis Lesion With Intralesional Injection of Sodium Thiosulfate at High Concentration. Wounds. 2019; 31:E54-E57.

-Dorf N, Maciejczyk M. Skin manifestations in diabetes-what is new? Front Med (Lausanne). 2025; 12:1640144.

-Abate MCMO MCMO, Aroucha PMT, Nóbrega DVMD, Rocha IPM, Soares SD, Reis AA, Paliares IC, Giuffrida FMA, Dib SA, Reis AF, Sa JR. Cutaneous manifestations of diabetes mellitus: a narrative review. Einstein (Sao Paulo). 2025; 23:eRW1193.

-Kalra S, Verma R, Kumar A. Diabetic dermopathy: A vascular complication equivalent. J Pak Med Assoc. 2022; 72(6):1235-1236.

–Sibbald C, 2015; Zuluaga T, Pulavarty A, Caplan AS. Necrobiosis Lipoidica. JAMA Dermatol. 2026; 162(5):529-530.

-Lepe K, Riley CA, Hashmi MF, Salazar FJ. Necrobiosis Lipoidica. 2024 Jun 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.

–Schiefer-Niederkorn A, Sadoghi B, Binder B. Necrobiosis lipoidica in childhood: a review of literature with emphasis on therapy. J Dtsch Dermatol Ges. 2023; 21(10):1120-1129.

–Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: a review. Endocrinol Metab Clin North Am. 2013; 42:869-98.

–Sibbald C, Reid S, Alavi A. Necrobiosis Lipoidica. Dermatol Clin. 2015; 33:343-60.

–Grillo E, Rodriguez-Muñoz D, González-Garcia A, Jaén P. Necrobiosis lipoidica. Aust Fam Physician. 2014; 43:129-30.

–Matas-Nadal C, Fernández-Armenteros JM, Casanova Seuma JM, Vilardell F, Baradad M, Aguayo-Ortiz RS. Papular spreading necrobiosis lipoidica: a rare clinical presentation of this pathology. Clin Exp Dermatol. 2019; 44:e159-e160.

-Hammer E, Lilienthal E, Hofer SE, Schulz S, Bollow E, Holl RW; DPV Initiative and the German BMBF Competence Network for Diabetes Mellitus. Risk factors for necrobiosis lipoidica in Type 1 diabetes mellitus. Diabet Med. 2017; 34:86-92.

-Peckruhn M, Tittelbach J, Elsner P. Update: Treatment of necrobiosis lipoidica. J Dtsch Dermatol Ges. 2017; 15:151-157.

-Lim JZ, Ng NS, Thomas C. Prevention and treatment of diabetic foot ulcers. J R Soc Med. 2017; 110:104-109.

-Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023; 330(1):62-75.

-Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis †. Ann Med. 2017; 49:106-116.

-Carro GV, de Jesus FM, Ricci A. Diabetic Foot Osteomyelitis: Is it all the Same? Int J Low Extrem Wounds. 2025; 24(4):879-886.

-Castellino LM, Crisologo PA, Chhabra A, Öz OK. Diabetic Foot Infections. Infect Dis Clin North Am. 2025; 39(3):465-482.

-Blume P, Wu S. Updating the Diabetic Foot Treatment Algorithm: Recommendations on Treatment Using Advanced Medicine and Therapies. Wounds. 2018; 30:29-35.

-Bandyk DF. The diabetic foot: Pathophysiology, evaluation, and treatment. Semin Vasc Surg. 2018; 31:43-48.

-Noor S, Zubair M, Ahmad J. Diabetic foot ulcer–A review on pathophysiology, classification and microbial etiology. Diabetes Metab Syndr. 2015; 9:192-9.

-Ramirez-Acuña JM, Cardenas-Cadena SA, Marquez-Salas PA, Garza-Veloz I, Perez-Favila A, Cid-Baez MA, Flores-Morales V, Martinez-Fierro ML. Diabetic Foot Ulcers: Current Advances in Antimicrobial Therapies and Emerging Treatments. Antibiotics (Basel). 2019; 8. pii: E1939.

-Spanos K, Saleptsis V, Athanasoulas A, Karathanos C, Bargiota A, Chan P, Giannoukas AD. Factors Associated With Ulcer Healing and Quality of Life in Patients With diabetic Foot Ulcer. Angiology. 2017; 68:242-250.

-Rafique S, Dihowm H, Parveen S, Jakoby M. Insulin-Induced Acanthosis Nigricans. Cureus. 2025; 17(5):e8342.

-Hughes EK, Brady MF, Rawla P. Acanthosis Nigricans. 2023 Aug 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–

-Kalantari Y, Meier K, Ghoreschi K, Kinberger M, Solimani F. Sclerosing diseases of the skin. J Dtsch Dermatol Ges. 2025; 23(10):1282-1300.

-Pfeiffer C, Sunderkötter C. Differenzialdiagnosen sklerosierender Dermatosen: Scleroedema adultorum Buschke. Dermatologie (Heidelb). 2024; 75(3):232-236.

-Makary N, Razali Q. Diabetes-Associated Scleredema. N Engl J Med. 2024; 391(8):e15.

-Ranabahu M, Karunarathna W, Asanthi J, Dassanayake D, Senanayake H. Scleredema Diabeticorum: A Rare Metabolic Connective Tissue Manifestation of Type 2 Diabetes Mellitus Causing External Restrictive Lung Disease. Cureus. 2024; 16(5):e60374).

–Pereira M, Pinheiro RR, Lencastre A, Bártolo E. Scleredema diabeticorum. Dermatol Reports. 2022; 14(4):9477.

-Cojocaru A, Dorobanțu AM, Bălăceanu B, Tudose I, Orzan OA. A Rare Association of Disseminated Granuloma Annulare With Recurrent Uveitis. Cureus. 2024; 16(2):e53570.

-Ahlers C, Parker ER. A report of disseminated actinic granuloma: An unusually extensive presentation. SAGE Open Med Case Rep. 2023; 11:2050313X231195487.

-Qian YT, Liu JW, Liu W, Chen T, Tan Y, Ma DL. A Retrospective Study of 105 Patients with Elastolytic Giant Cell Granuloma and a Proposal for a New Clinical Classification. Acta Derm Venereol. 2022; 102:adv00684.

-Franklin M, Somach S. Granuloma annulare. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/skinnontumorgranulomaannulare.html. Visitado el 21 de septiembre de 2026.

-Trayes KP, Savage K, Studdiford JS. Annular Lesions: Diagnosis and Treatment. Am Fam Physician. 2018; 98(5):283-291.

-Foroohar T, Berk-Krauss J, Caplan AS, Leung TH, Barbieri JS, Wanat KA, Nelson C, Mangold AR, English JC 3rd, Rosenbach M, Shields BE, Damsky W. Granuloma annulare: An updated review of epidemiology, molecular pathogenesis, and management. J Am Acad Dermatol. 2026: S0190-9622(26)02959-2.

-Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: a review. Endocrinol Metab Clin North Am. 2013; 42(4):869-98

-Chouk C, Litaiem N. Bullosis Diabeticorum. 2024 Jan 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.

–Dorf N, Maciejczyk M. Skin manifestations in diabetes-what is new? Front Med (Lausanne). 2025; 12:1640144.

-Hou M, Amed S, Goldman RD. Insulin pump complications among children with diabetes. Can Fam Physician. 2022; 68(12):893-895.

-Cohen B, Cadesky A, Jaggi S. Dermatologic manifestations of thyroid disease: a literature review. Front Endocrinol (Lausanne). 2023; 14:1167890.

-Mullin GE, Eastern JS. Cutaneous signs of thyroid disease. Am Fam Physician. 1986; 34(4):93-8; Doshi DN, Blyumin ML, Kimball AB. Cutaneous manifestations of thyroid disease. Clin Dermatol. 2008; 26(3):283-7.

-Kanat Z, Karaca Karagöz Z, Baskaya Dogan F, Türkmen D, Altunışık N, Şener S. Cutaneous manifestations in autoimmune thyroid disease: a cross-sectional study. Cutan Ocul Toxicol. 2026; 45(3):436-444.

–Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol. 2005; 6:295-309.

-Sabanova EA, Fadeyev VV, Potekaev NN, Lvov AN. Pretibial myxedema: pathogenetic features and clinical aspects. Probl Endokrinol (Mosk). 2019; 65:134-138.

-Anagnostis P, Artzouchaltzi A, Grekou A, Paschou SA, Gerou S, Tzalokostas V. Pretibial myxedema in a euthyroid patient. Hormones (Athens). 2018; 17:133-135.

-Zhang F, Lin XY, Chen J, Peng SQ, Shan ZY, Teng WP, Yu XH. Intralesional and topical glucocorticoids for pretibial myxedema: A case report and review of literature. World J Clin Cases. 2018; 6:854-861.

-Chatterjee R, Chandra A, Pramanik N, Sil A. Pretibial Myxedema as the Presenting Manifestation of Graves Disease. Am J Med. 2024; 137(10):e188-e189.

-Lebreton O, Seddiki R, Abba S, Vignes S. Myxœdème prétibial pseudo-tumoral après une maladie de Basedow: un diagnostic différentiel du lymphœdème. Rev Med Interne. 2023; 44(12):641-645.

-Nguyen VB, Nguyen VVH, Van Le C, Linh PNT, Thi XN, Vo TT. Pretibial myxedema in Grave’s disease: A case report and treatment review of the literature. Clin Case Rep. 2024; 12(2):e8478.

-Hathi D, Goswami S, Sengupta N, Baidya A, Gaikwad PM, Das N, Tarenia SS, Oswal R. A Case of Elephantiasic Pretibial Myxedema Successfully Treated With Intralesional Triamcinolone Acetate. Cureus. 2022; 14(9):e29234.

-Reyes MP, Cabrera J, Singh J, Turnbull D. Teprotumumab for Treatment of Pretibial Myxedema. JCEM Case Rep. 2023; 1(1):luac037.

-Regina J, Moret Bochatay M. Hippocratisme digital. Rev Med Suisse. 2024; 20(889):1781-1783.

-Essouma M, Nkeck JR, Agbor VN, Noubiap JJ. Epidemiology of Digital Clubbing and Hypertrophic Osteoarthropathy: A Systematic Review and Meta-analysis. J Clin Rheumatol. 2022; 28(2):104-110.

-Watanabe D, Tsujioka Y, Nakato D, Yamada M, Suzuki H, Ohnishi T, Tamai N, Kijima T, Takenouchi T, Miya F, Narumi S, Kosaki K. Digital clubbing without hypoxia for lysinuric protein intolerance. Eur J Med Genet. 2024; 71:104967.

-Cohen, 2023.

-Perepelova MA, Zaitseva EL, Bessmertnaya EG, Grusha YO, Sviridenko NY, Galstyan GR. An integrated approach to the treatment of pretibial myxedema based on pulse therapy with prednisolone and electrical neuromyostimulation (FREMS-therapy) in a patient with Graves’ disease and thyroid eye disease. Probl Endokrinol (Mosk). 2023; 69(4):32-379.

-Vaidya N, Acharya N, Katila S, Adhikari S, Pandey U. Pachydermoperiostosis: a case report of initial improvement with etoricoxib. Ann Med Surg (Lond). 2023; 85(10):5153-5157.

-Heymans B, Meersseman W. Porphyria: awareness is the key to diagnosis! Acta Clin Belg. 2022; 77(3):703-709.

-Leaf RK, Dickey AK. Porphyria cutanea tarda: a unique iron-related disorder. Hematology Am Soc Hematol Educ Program. 2024; 2024(1):450-456.

-Mistegård J, Christiansen AL, Vestergaard C, Wulf HC, Lorentzen HF. Porphyria cutanea tarda. Ugeskr Laeger. 2025; 187(38):V11240832.

–Muray S, Casanova JM, Marco MP, Craver L, Martín M, Fernández E. Porfiria cutanea tarda, hemodialisis y hepatopatia VHC. Nefrologia. 2002; 22:570-3) se debe realizar un tratamiento combinado específico.

-Rudnick S, Phillips J, Bonkovsky H; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Familial Porphyria Cutanea Tarda. 2013 Jun 6 [updated 2022 Jun 9]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews^® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.

-Gonzalez-Mosquera LF, Sonthalia S. Acute Intermittent Porphyria. 2023 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.

-Valbuena Valecillos A, Yatham P, Alderman M, Shapiro L, Tiozzo E, Gober J. Acute Intermittent Porphyria: A Review and Rehabilitation Perspective. Cureus. 2023; 15(8):e44260.

-Sardh E, Barbaro M. Acute Intermittent Porphyria. 2005 Sep 27 [updated 2024 Feb 8]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews^® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.

-de Schaetzen V, Richert B, de la Brassinne M. Les xanthomes. Rev Med Liege. 2004; 59:46-50.

-Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014; 158:181-8.

-Santiago L, Pinho A, Cardoso JC. Xantomas Eruptivos: Manifestação Cardinal de Distúrbio Metabólico Grave. Acta Med Port. 2018; 31:219-222.

-Duzayak S, Sayiner ZA, Erkılıç S, Inaloz HS. Acute pancreatitis with eruptive xanthoma. BMJ Case Rep. 2017; pii: bcr-2017-221543.

-Kong MX, Zhang Q, Cao L, Zhao C, Ru GQ, Bi Q. Familial hypercholesterolaemia with tuberous and tendinous xanthomas: case report and mutation analysis. Clin Exp Dermatol. 2015; 40:765-9.

-Koopal C, Visseren FL, Marais AD, Westerink J, Spiering W. Tendon xanthomas: Not always familial hypercholesterolemia. J Clin Lipidol. 2016; 10:1262-5.

-Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014; 158:181-8.

-Bell A, Saleh HM. Xanthoma. 2026 Sep 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.

-Roy N, Gaudet D, Brisson D. Palmar Striated Xanthomas in Clinical Practice. J Endocr Soc. 2022; 6(8):bvac103.

-Blair K, Shah SS. Xanthelasma Palpebrarum. 2026 Jul 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.

–Yee DA, Zhou AE, Khachemoune A. Examining treatment strategies for xanthelasma palpebrarum: a comprehensive literature review of contemporary modalities. Arch Dermatol Res. 2024; 316(5):149.

-Tang KY, Wu MY, Li J. Eruptive Xanthomas. JAMA Dermatol. 2023; 159(4):449.

-Marogi EP, Ohiomoba RO, Stone NJ. Eruptive Xanthomas: Importance of Recognition to Reduce Delay of Effective Triglyceride Reduction. Am J Med. 2022; 135(4):444-447

-Girish T, Ramesh KS, Shetty SK, Rao A R S. Two siblings with tuberous xanthomas: case report. BMJ Case Rep. 2025; 18(3):e262973.

–Kazmi A, Frewen J, McDonald B, Davison J, O’Toole E. Tuberous xanthoma secondary to homozygous familial hypercholesterolaemia: a life-threatening diagnosis. Clin Exp Dermatol. 2022; 47(12):2336-2338.

-Narasimhan M, Muthu P, Ramakrishnan R, Sriram V. Tuberous xanthoma with cardiac failure in a child. J Family Med Prim Care. 2022; 11(6):3290-3292.

-Federico A, Gallus GN. Cerebrotendinous Xanthomatosis. 2024. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews^® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.

-Gomes N, Cerejeira A, Brito I, Trigo F, Silva R, Moreira E, Azevedo F. Normolipemic Plane Xanthoma. Skinmed. 2022; 20(3):228-230.

-Cerqueira C, Sobreiro Silva J, Moreira Nogueira C, Ribeiro M, Vieira AP. Diffuse Normolipemic Plane Xanthoma Associated With Monoclonal Gammopathy. Cureus. 2025; 17(7):e89071.

-Klapproth H, Tantcheva-Poór I, Fabri M. Necrobiotic Xanthogranuloma. Br J Dermatol. 2025; 193(5):1036.

–Tessier-Kay M, Sarfo A. Necrobiotic xanthogranuloma. Clin Dermatol. 2026: S0738-081X(26)00202-6.

-King HL, Benedetti GB, Keller JJ, DeLoughery TG, Shatzel JJ, Martens KL. Dermatologic manifestations of hematologic disorders. Ann Hematol. 2024; 103(10):3889-3903.

-Maronese CA, Derlino F, Moltrasio C, Cattaneo D, Iurlo A, Marzano AV. Neutrophilic and eosinophilic dermatoses associated with hematological malignancy. Front Med (Lausanne). 2024; 10:1324258.

-Chen KR. Cutaneous vasculitis in autoinflammatory diseases. J Dermatol. 2024; 51(2):150-159).

-Georgesen C, Fox LP, Harp J. Retiform purpura: A diagnostic approach. J Am Acad Dermatol. 2020; 82(4):783-796.

-Chatterjee S. Livedo reticularis. Lancet Rheumatol. 2023; 5(3):e166.

-Pincelli MS, Echavarria AMJ, Criado PR, Marques GF, Morita TCAB, Valente NYS, de Carvalho JF. Livedo Racemosa: Clinical, Laboratory, and Histopathological Findings in 33 Patients. Int J Low Extrem Wounds. 2021; 20(1):22-28.

-Perera TB, Murphy-Lavoie HM. Purpura Fulminans. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.

-Leeolou MC, Rieger KE, Yeh JE. Livedoid vasculopathy. Dermatol Online J. 2023; 29(5). doi: 10.5070/D329562414.

–Jenei A, Tzankov A. Diagnostic approach to leukemia cutis: A differential diagnostic step-by-step algorithm. Am J Clin Pathol. 2025; 163(3):395-405.

-Mandal AP, Das R, Sengupta M, Chatterjee U. Leukemia cutis – A case of cutaneous manifestation of acute monoblastic leukemia. J Cancer Res Ther. 2023; 19(3):826-828.

-Whittington CP, Ross CW, Ramirez JA, Lowe L, Brown N, Hristov AC. Myelodysplasia Cutis. Arch Pathol Lab Med. 2024; 148(4):385-389.

–Franz T, Hubbuch M, Rupp S, Brockow K. Challenges in Cutaneous Mastocytosis. Immunol Allergy Clin North Am. 2025; 45(4):589-602.

-Abu-Dayeh A, Karzoun MZ, Giubellino A. Cutaneous mastocytosis. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/skintumornonmelanocyticmastcell.html. Accessed October 8th, 2026).

-Leguit RJ, Wang SA, George TI, Tzankov A, Orazi A. The international consensus classification of mastocytosis and related entities. Virchows Arch. 2023; 482(1):99-112.

-Akin C, Arock M, Carter MC, George TI, Valent P. Mastocytosis. Nat Rev Dis Primers. 2025; 11(1):30.

-Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023; 98(7):1097-1116.

-Nemat K, Abraham S. Cutaneous mastocytosis in childhood. Allergol Select. 2022; 6:1-10).

–Miyashiro D, Sanches JA. Paraneoplastic skin disorders: a review. G Ital Dermatol Venereol. 2016; 151:55-76.

-Gießen-Jung C, Wollenberg A, Reinholz M. [Paraneoplasms of the skin]. Internist (Berl). 2018; 59:134-144.

-Geng G, Yu X, Jiang J, Yu X. Aetiology and pathogenesis of paraneoplastic autoimmune disorders. Autoimmun Rev. 2019: 102422.

–Wick MR, Patterson JW. Cutaneous paraneoplastic syndromes. Semin Diagn Pathol. 2019; 36:211-228.

–Cheng E, Roy DB, Magro CM. A case of acanthosis nigricans coexisting with mycosis fungoides.Dermatol Online J. 2015; 21. pii: 13030/qt3sw2t3b8.

-Alter M, Mengoni M, Gaffal E. Cutaneous manifestations of internal malignancy. J Dtsch Dermatol Ges. 2020; 18(5):456-469.

-Didona D, Rallo A, Carugno A, Paolino G. Paraneoplastic Dermatoses: A Clue for Underlying Malignancies. J Clin Med. 2025; 14(3):1014.

-Singhaviranon S, Klufas T, Aiudi D. Paraneoplastic dermatoses in patients with hematologic malignancy. Clin Dermatol. 2026:S0738-081X(26)00201-4.

-Moore RL, Devere TS. Epidermal manifestations of internal malignancy. Dermatol Clin. 2008; 26(1):17-29.

-Roser A, Pajot C, Kettani S, Michalak S, Le Clech C. Acanthosis nigricans malin révélant un cholangiocarcinome. Rev Med Interne. 2019; 40:750-753.

-Valejo Coelho MM, Prokop J, Fernandes C. Acanthosis Nigricans Maligna. JAMA Dermatol. 2019; 155(9):1069.

-Liu Y, Xu X, Yang Y, Hu H, Jiang X, Xiong X, Meng W. Malignant acanthosis nigricans and diseases with extensive oral papillary hyperplasia. Clin Exp Dermatol. 2022; 47(4):651-657.

-Rizwan M, Iftikhar N, Sarfraz T, Ullah O. Malignant Acanthosis Nigricans: An Indicator of Internal Malignancy. J Coll Physicians Surg Pak. 2019; 29(9):888-890.

–Nguyen S, Grosber M, Gutermuth J. Acrokeratosis Can Be a Warning Sign of an Underlying Malignancy. Eur J Case Rep Intern Med. 2019; 6:001108.

-Räßler F, Goetze S, Elsner P. Acrokeratosis paraneoplastica (Bazex syndrome) – a systematic review on risk factors, diagnosis, prognosis and management.J Eur Acad Dermatol Venereol. 2017; 31:1119-1136.

-Gül Ü. Acral manifestations of paraneoplastic and collagen vascular diseases. Clin Dermatol. 2017; 35:50-5.

-Macca L, Manuella L, Taibi R, Guarneri C. Acrokeratosis of Bazex as a sign of thyroid cancer: first description and review of thyroid-associated paraneoplastic dermatoses. Eur Rev Med Pharmacol Sci. 2022; 26(12):4367-4370.

-Rao AG, Farheen SS, Amit K, Reddy UD, Aparna K, Kranthi J, Hukkani R. Erythema Gyratum Repens Associated With Diffuse B-cell Lymphoma-Report of A Rare Case. Indian J Dermatol. 2019; 64:338.

-Kazandjieva J, Bogdanov G, Bogdanov I, Tsankov N. Figurate annulare erythemas. Clin Dermatol. 2023; 41(3):368-375.

-Clyatt G, Cole J. A Unique Case of Localized Palmar Erythema Annulare Centrifugum. Cureus. 2022; 14(6):e25718.

-Quattri E, Zussino M, Marzano AV, Genovese G. Lung cancer-associated erythema gyratum repens rapidly evolving to erythroderma. Ital J Dermatol Venerol. 2023; 158(1):71-72.

-Marinho B, Velho G, Santos MD. Cutaneous Manifestations as a Sentinel of Colorectal Cancer: A Case Report. J Clin Med. 2026; 15(7):2789.

-V’lckova-Laskoska M, Balabanova-Stefanova M, Arsovska-Bezhoska I, Caca-Biljanovska N, Laskoski D. Necrolytic Migratory Erythema: Complete Healing after Surgical Removal of Pancreatic Carcinoma. Acta Dermatovenerol Croat. 2018; 26:329-332.

-Wick MR, Patterson JW. Cutaneous paraneoplastic syndromes. Semin Diagn Pathol. 2019; 36(4):211-228.

-Didona D, 2025.

-Wyatt JP, Anderson HF, Greer KE, Cordoro KM. Acquired hypertrichosis lanuginosa as a presenting sign of metastatic prostate cancer with rapid resolution after treatment. J Am Acad Dermatol. 2007; 56(2 Suppl):S45-7.

-Slee PH, van der Waal RI, Schagen van Leeuwen JH, Tupker RA, Timmer R, Seldenrijk CA, van Steensel MA. Paraneoplastic hypertrichosis lanuginosa acquisita: uncommon or overlooked? Br J Dermatol. 2007;157(6):1087-92.

-Gómez-Arias PJ, Vélez García-Nieto AJ, Salido-Vallejo R. Paraneoplastic hypertrichosis lanuginosa acquisita. Indian J Dermatol Venereol Leprol. 2022; 88(4):525-526.

-Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, Moliterni E, Donati M, Ciofalo A, Granata G, Ranuzzi P, Falasca V, Calvieri S. Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy. Int J Mol Sci. 2017; 18. pii: E2532.

–Tirado-Sánchez A, Bonifaz A. Paraneoplastic Pemphigus. A Life-Threatening Autoimmune Blistering Disease. Actas Dermosifiliogr. 2017; 108:902-910.

-Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol. 2013; 54:241-50.

-Maruta CW, Miyamoto D, Aoki V, Carvalho RGR, Cunha BM, Santi CG. Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview. An Bras Dermatol. 2019; 94:388-398.

-Anderson HJ, Huang S, Lee JB. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part I. Clinical overview and pathophysiology. J Am Acad Dermatol. 2024; 91(1):1-10.

-Huang S, Anderson HJ, Lee JB. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part II. Diagnosis and management. J Am Acad Dermatol. 2024; 91(1):13-22.

-Zou M, Zhan K, Zhang Y, Li L, Li J, Gao J, Liu X, Li W. A systematic review of paraneoplastic pemphigus and paraneoplastic autoimmune multiorgan syndrome: Clinical features and prognostic factors. J Am Acad Dermatol. 2025; 92(2):307-310.

–Stoyanov GS, Dzhenkov DL, Tzaneva M. Thrombophlebitis Migrans (Trousseau Syndrome) in Pancreatic Adenocarcinoma: An Autopsy Report. Cureus. 2019; 11:e5528.

–Cunha DG, Campos-do-Carmo G, Marujo JM, Verardino GC. Paraneoplastic Sweet’s syndrome. An Bras Dermatol. 2018; 93:576-578.

-Martires K, Callahan S, Terushkin V, Brinster N, Leger M, Soter NA. Eosinophilic dermatosis of hematologic malignancy. Dermatol Online J. 2016; 22. pii: 13030/qt8467m0j9.

-Weisshaar E, Weiss M, Mettang T, Yosipovitch G, Zylicz Z; Special Interest Group of the International Forum on the Study of Itch. Paraneoplastic itch: an expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI). Acta Derm Venereol. 2015; 95:261-5.

-Rowe B, Yosipovitch G. Paraneoplastic Itch Management. Curr Probl Dermatol. 2016; 50:149-54.

-Matsuda-Hirose H, Nashimoto Y, Tanabe A, Ogata M, Iwao M, Mizukami K, Nishida H, Hatano Y. Thrombophlebitis Migrans As the Prodrome of Adult T-Cell Leukemia-Lymphoma. Ann Dermatol. 2022 Aug;34(4):312-314.

-Fazeli B, Poredos P, Schernthaner G, Stephen E, Kozak M, Catalano M, Pecsvarady Z, Patel M, Al Salman MM, Altarazi L, Muhammad Bashar AH, Chua B, Cvjetko I, Desai S, Erer D, Hussein E, Gaddikeri P, Ionac M, Iwai T, Karahan O, Kota A, Kroger K, Kumar PP, Malecki R, Marcoccia A, Pandey SR, Ravari H, Samuel V, Selvaraj D, Sermsathanasawadi N, Sharebiani H, Szuba A, Taheri H, Zor MH, Liew A. An International Delphi Consensus on Diagnostic Criteria for Buerger’s Disease. Ann Vasc Surg. 2022; 85:211-218.

–Vrooman E, Grant-Kels JM. Neutrophilic dermatoses. Clin Dermatol. 2026: S0738-081X(26)00206-3.

-Titou H, Bouhamidi A. Sweet syndrome in patients with and without malignancy: a retrospective study of 66 cases from a tertiary care centre. Eur J Dermatol. 2024; 34(5):517-524).

-Nguyen DC, Hamilou Z, Bonnardeaux E, Blais N, de Vries-Brilland M. A Rare Case of Metastatic Urethral Squamous Cell Carcinoma Presenting with Paraneoplastic Sweet Syndrome and Treated with Pembrolizumab. Curr Oncol. 2025; 32(12):683.

-Bagos-Estevez AG, Moore S, Turner L, Baldwin B. A Case of Bullous Sweet’s Syndrome Associated With Esophageal Adenocarcinoma. Cureus. 2024; 16(1):e52954.

-Aghabeigi S, Ahmadvand N, Mosavi Mirkalaie SM, Sedighi Moghadam A, Aref-Eshghi A. When the Skin Speaks for the Bone Marrow: Sweet Syndrome and Pancytopenia as the Initial Manifestation of Occult AML. Int J Hematol Oncol Stem Cell Res. 2026; 20(1):110-116.

-Wang B, Qian K, Liu H, Huang Y, Wang Y, Li L, Yu F. Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report. Front Med (Lausanne). 2026; 13:1839456.

-Çetinarslan T, Avcı BT, Pehlivan FS, Aydoğdu İ, Temiz P, Ermertcan AT. Clinicopathologic Spectrum of Dermatological Diseases in Patients with Acute Myeloid Leukemia (AML): A Retrospective Study in AML Patients with Cutaneous Manifestations. Indian J Hematol Blood Transfus. 2026; 42(1):138-145.

-Mammen AL. Paraneoplastic myopathies. Handb Clin Neurol. 2024; 200:327-332.

-Orton C, Topham C, Madigan LM. Paraneoplastic Dermatomiositis. Am J Med. 2022; 135(8):969-971.

-Callen JP. Dermatomyositis. JAMA Dermatol. 2023; 159(9):1016.

–Laidler NK. Dermatomyositis as a paraneoplastic phenomenon in oesophageal cancer. BMJ Case Rep. 2018; 11.

-Aguayo-Ortiz R, Casanova-Seuma JM. Dermatomiositis amiopática. Piel: formación continuada en dermatología, 2012; 27:77-81.

-Didona D, Solimani F, Caposiena Caro RD, Sequeira Santos AM, Hinterseher J, Kussini J, Cunha T, Hertl M, Didona B. Dermatomyositis: a comprehensive review of clinical manifestations, serological features, and therapeutic approaches. Ital J Dermatol Venerol. 2023; 158(2):84-98.

-Aliu A, Wehry UP, Oellig F, Gambichler T, Burmann SN, Vidakovic M, Kionke J, Distler JHW, Györfi AH, Müller VL, Kreuter A. Periorbital heliotrope erythema with edema as a potential clinical marker of paraneoplastic Dermatomyositis – a case series. J Dtsch Dermatol Ges. 2026; 24(6):731-736.

-Strickley JD, Jenson AB, Jung JY. Cutaneous Metastasis. Hematol Oncol Clin North Am. 2019; 33(1):173-197.

-Vernemmen AIP, Li X, Roemen GMJM, Speel EM, Kubat B, Hausen AZ, Winnepenninckx VJL, Samarska IV. Cutaneous metastases of internal malignancies: a single-institution experience. Histopathology. 2022; 81(3):329-341.

-Iorga PG, Dragomirescu A, Scurtu LG, Simionescu O. An Update on Cutaneous Metastases of Internal Malignancies. Medicina (Kaunas). 2025; 61(9):1570.

-Hussein MR. Skin metastasis: a pathologist’s perspective. J Cutan Pathol. 2010; 37(9):e1-20.

-Li X, Roemen GMJM, Speel EM, Kubat B, Hausen AZ, Winnepenninckx VJL, Samarska IV. Cutaneous metastases of internal malignancies: a single-institution experience. Histopathology. 2022; 81(3):329-341.

-Gerber AA, Chen R, Timmons CF, Hoang MP. Cutaneous Metastases of Unusual Tumor Types: Retrospective Single-Institution Analysis and Literature Review. Am J Dermatopathol. 2026; 48(6):415-428.

-Lee HW, Jose CC, Cuddapah S. Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases. Semin Cancer Biol. 2021; 76:99-109.

-Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15(3):178-96.

-Simeone P, Trerotola M, Franck J, Cardon T, Marchisio M, Fournier I, Salzet M, Maffia M, Vergara D. The multiverse nature of epithelial to mesenchymal transition. Semin Cancer Biol. 2019; 58:1-10.

-Fontana R, Mestre-Farrera A, Yang J. Update on Epithelial-Mesenchymal Plasticity in Cancer Progression. Annu Rev Pathol. 2024; 19:133-156.

-Mortezaee K, Majidpoor J, Kharazinejad E. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med Oncol. 2022; 39(12):193.

-Lengrand J, Pastushenko I, Vanuytven S, Song Y, Venet D, Sarate RM, Bellina M, Moers V, Boinet A, Sifrim A, Rama N, Ducarouge B, Van Herck J, Dubois C, Scozzaro S, Lemaire S, Gieskes S, Bonni S, Collin A, Braissand N, Allard J, Zindy E, Decaestecker C, Sotiriou C, Salmon I, Mehlen P, Voet T, Bernet A, Blanpain C. Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature. 2023; 620(7973):402-408.

-Gurung S, Budden T, Mallela K, Jenkins B, von Kriegsheim A, Manrique E, Millán-Esteban D, Romero-Camarero I, Amaral F, Craig S, Durao P, Pozniak J, Stennett L, Smith D, Ashton G, Baker A, Zeng K, Fruhwirth G, Sanz-Moreno V, Marques J, Koulman A, Marine JC, Somervaille TCP, Motta L, Gaudy-Marqueste C, Nagore E, Virós A. Stromal lipid species dictate melanoma metastasis and tropism. Cancer Cell. 2025; 43(6):1108-1124.

-Kamińska-Winciorek G, Pilśniak A, Piskorski W, Wydmański J. Skin metastases in the clinical and dermoscopic aspects. Semin Oncol. 2022; 49(2):160-169.

-Wang S, Tang W, Jin F, Luo H, Yang H, Wang Y. Comprehensive Analysis of Lung Cancer Metastasis: Sites, Rates, Survival, and Risk Factors-A Systematic Review and Meta-Analysis. Clin Respir J. 2025; 19(7):e70107.

-Joshi UM, Kashani-Sabet M, Kirkwood JM. Cutaneous Melanoma: A Review. JAMA. 2025; 334(23):2113-21259.

-Contreras-Steyls M, Herrera-Acosta E, Moyano B, Herrera E. Melanoma primario con metástasis cutáneas múltiples. Actas Dermosifiliogr. 2011; 102(3):226-9.

-Shah AA, Casciola-Rosen L. Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol. 2015; 27:563-70.

-Santos-Faria D, Leite Silva J, Sousa-Neves J, Ramos Rodrigues J, Afonso C, Peixoto D. Systemic sclerosis and myositis as a paraneoplastic syndrome secondary to multiple myeloma. Acta Reumatol Port. 2018; 43:316-317.

–Alcaraz I, Cerroni L, Rütten A, Kutzner H, Requena L. Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. Am J Dermatopathol. 2012; 34:347-93.

-Strickley JD, Jenson AB, Jung JY. Cutaneous Metastasis. Hematol Oncol Clin North Am. 2019; 33:173-197.

-Hussein MR. Skin metastasis: a pathologist’s perspective. J Cutan Pathol. 2010; 37:e1-20.

-Hager CM, Cohen PR. Cutaneous lesions of metastatic visceral malignancy mimicking pyogenic granuloma. Cancer Invest. 1999; 17:385-90.

-Otsuka I. Cutaneous Metastases in Ovarian Cancer. Cancers (Basel). 2019; 11. pii: E1292.

-Vila Justribó M, Casanova Seuma JM, Portero L, Egido R. Metástasis cutáneas como primera manifestación de carcinoma broncogénico. Arch Bronconeumol 1994; 30: 314-6.

-Mollet TW, Garcia CA, Koester G. Skin metastases from lung cancer. Dermatol Online J. 2009; 15:1.

–Feeney KJ, Mastrangelo MJ. Intralesional therapy for in-transit and satellite metastases in melanoma. Surg Oncol Clin N Am. 2015; 24:299-308.

-Sandoval-Leon AC, Drews-Elger K, Gomez-Fernandez CR, Yepes MM, Lippman ME. Paget’s disease of the nipple. Breast Cancer Res Treat. 2013; 141:1-12.

-Markarian S, Holmes DR. Mammary Paget’s Disease: An Update. Cancers (Basel). 2022; 14(10):2422.

-Adams SJ, Kanthan R. Paget’s disease of the male breast in the 21st century: A systematic review. Breast. 2016; 29:14-23.

–Hudson-Phillips S, Cox K, Patel P, Al Sarakbi W. Paget’s disease of the breast: diagnosis and management. Br J Hosp Med (Lond). 2023; 84(1):1-8.

–Yoshino R, Kitada M, Inao T, Takahashi K, Ito A, Ujiie N, Yasuda S, Hatanaka N. Clinical and Pathological Characteristics of the Mammary Paget’s Disease: A Single-Center Retrospective Study in Japan. Cancer Invest. 2025; 43(10):903-910.

-Moore SA, Notgrass HM, Vandergriff TW, Sahoo S. Mammary Paget’s Disease of the Male Breast: A Rare Case With an Unusual Immunohistochemical Profile. Int J Surg Pathol. 2019:1066896919874878

-Geffroy D, Doutriaux-Dumoulins I, Labbe-Devilliers C, Meingan P, Houdebine S, Sagan C, Dejode M, Ricaud-Couprie M. Maladie de Paget du mamelon et principaux diagnostics différentiels. J Radiol. 2011; 92:889-98.

-Fernández-Figueras MT, Puig L, Casanova JM, Musulén E, Matías-Guiu X, Navas-Palacios JJ. Pigmented epidermotropic ductal carcinoma of the breast in a male. Ultrastructural evidence of melanocytic colonization and melanin transfer to the tumor. J Cutan Pathol. 1995; 22:276-80.

-Volontè M, Barruscotti S, Feltri M, Brazzelli V, Tomasini CF, Vassallo C. A monolateral pigmented lesion of the nipple. Clin Exp Dermatol. 2022; 47(12):2330-2332.

-Drews-Elger K, Sandoval-Leon AC, Ergonul AB, Jegg AM, Gomez-Fernandez C, Miller PC, El-Ashry D, Lippman ME. Paget’s disease of the nipple in a Her2-positive breast cancer xenograft model. Breast Cancer Res Treat. 2019. doi: 10.1007/s10549-019-05490-8.

-Yasir M, Khan M, Lotfollahzadeh S. Mammary Paget Disease. 2023 Jun 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.

-Wei Y, Zhu Q, Li J, Jiang Y. Clinical and Sonographic Features of Mammary Paget’s Disease. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2017; 39(3):396-400.

-Seetharam S, Fentiman IS. Paget’s disease of the nipple. Womens Health (Lond). 2009; 5(4):397-402.

-Lin CW, Chiang MH, Tam KW. Treatment of Mammary Paget Disease: A systematic review and meta-analysis of real-world data. Int J Surg. 2022; 107:106964.

-Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024; 22(5):331-357.

-Lopes Filho LL, Lopes IM, Lopes LR, Enokihara MM, Michalany AO, Matsunaga N. Mammary and extramammary Paget’s disease. An Bras Dermatol. 2015; 90:225-31.

-Shah RR, Shah K, Wilson BN, Tchack M, Busam KJ, Moy A, Leitao MM, Cordova M, Neumann NM, Smogorzewski J, Nguyen KA, Hosein S, Dafinone M, Schwartz RA, Rossi A. Extramammary Paget disease. Part I. epidemiology, pathogenesis, clinical features, and diagnosis. J Am Acad Dermatol. 2024; 91(3):409-418.

-Martinez MJ, Oh CS, Young T, Meehan S, Hall A, Zampella JG. Cutaneous Diseases of Penoscrotal Skin-Part I: Benign and Neoplastic Lesions. J Am Acad Dermatol. 2025; 93(3):585-600.

-Bahsas-Zaky O, Puckett Y. Extramammary Paget Disease. 2026 Jan 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.

-Primo WQSP, Primo GRP, Basilio DB, Machado KK, Carvalho JP, Carvalho FM. Vulvar Paget disease secondary to high-grade urothelial carcinoma with underlying massive vascular embolization and cervical involvement: case report of unusual presentation. Diagn Pathol. 2019; 14(1):125.

-Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Downing MB, Aasi SZ, Aung PP, Barker CA, Bolotin D, Bordeaux JS, Cartee TV, Chandra S, Cho NL, Choi JN, Chung KY, Cliby WA, Dorigo O, Eisen DB, Fujisawa Y, Golda N, Halfdanarson TR, Iavazzo C, Jiang SIB, Kanitakis J, Khan A, Kim JYS, Kuzel TM, Lawrence N, Leitao MM Jr, MacLean AB, Maher IA, Mittal BB, Nehal KS, Ozog DM, Pettaway CA, Ross JS, Rossi AM, Servaes S, Solomon MJ, Thomas VD, Tolia M, Voelzke BB, Waldman A, Wong MK, Zhou Y, Arai N, Brackett A, Ibrahim SA, Kang BY, Poon E, Alam M. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncol. 2022; 8(4):618-628.

-Nasioudis D, Bhadra M, Ko EM. Extramammary Paget disease of the vulva: Management and prognosis. Gynecol Oncol. 2020; 157(1):146-150.

-Shah RR, Shah K, Wilson BN, Leitao MM, Smogorzewski J, Nguyen KA, Crane C, Funt SA, Hosein S, Dafinone M, Rossi A. Extramammary Paget disease. Part II. Evidence-based approach to management. J Am Acad Dermatol. 2024; 91(3):421-430.

-Mammino JR, Daze RP, Mammino J. Fungal Masquerader: A Case Report of Extramammary Paget’s Disease Treated with Radiotherapy. Cureus. 2019; 11(10):e5937.

-Kibbi N, Owen JL, Worley B, Alam M; Extramammary Paget’s Disease Guideline Study Group. Recommended guidelines for screening for underlying malignancy in extramammary Paget’s disease based on anatomic subtype. J Am Acad Dermatol. 2025; 92(2):261-268.